April 4, 2012
Due to the planned maintenance of the Canadian National Research Unit (NRU) Mo-99 reactor shutdown, the United States will be facing a temporary shortage of Xenon-133 (Xe-133) for approximately one month. As of now, a replacement supply is unavailable as the alternative supplier commercially approved for the U.S. market is also unable to produce the product at the time.
Xe-133 is a critically important diagnostic tool that is instrumental in the timely and accurate diagnosis of a number of pulmonary conditions, including pulmonary embolism, a condition that is potentially fatal for patients. The use of Xe-133 is highly used by clinicians during emergency procedures in order to prevent potentially fatal conditions, including those involving problems with cerebral blood flow.
The SNM will keep you updated on any changes that may occur.